In this episode, Jason Schafer, PharmD, MPH, explores key considerations for the use of long-acting injectable pre-exposure prophylaxis (PrEP).- Listen as he gives his perspectives on:- The FDA approval of long-acting cabotegravir for PrEP- Healthcare professionals’ clinical concerns with long-acting injectable antiretroviral therapy- Considerations for long-acting cabotegravir as PrEPDosing and administrationManaging missed dosesDiscontinuationDelays in HIV diagnoses found in the HPTN 083 study in men- CDC recommendations for HIV screening while receiving PrEPPresenter:Jason Schafer, PharmD, MPHProfessor and Vice ChairJefferson College of PharmacyThomas Jefferson UniversityPhiladelphia, Pennsylvania Follow along with the slides at: https://bit.ly/3wugMOCSee the entire program at: https://bit.ly/3q2DlGd Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related